TY - JOUR
T1 - COVID-19 safe and fully operational radiotherapy
T2 - An AIRO survey depicting the Italian landscape at the dawn of phase 2
AU - on the behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)
AU - Jereczek-Fossa, Barbara Alicja
AU - Pepa, Matteo
AU - Zaffaroni, Mattia
AU - Marvaso, Giulia
AU - Bruni, Alessio
AU - Buglione di Monale e Bastia, Michela
AU - Catalano, Gianpiero
AU - Filippi, Andrea Riccardo
AU - Franco, Pierfrancesco
AU - Gambacorta, Maria Antonietta
AU - Genovesi, Domenico
AU - Iatì, Giuseppe
AU - Magli, Alessandro
AU - Marafioti, Luigi
AU - Meattini, Icro
AU - Merlotti, Anna
AU - Mignogna, Marcello
AU - Musio, Daniela
AU - Pacelli, Roberto
AU - Pergolizzi, Stefano
AU - Tombolini, Vincenzo
AU - Trovo, Marco
AU - Leonardi, Maria Cristina
AU - Ricardi, Umberto
AU - Magrini, Stefano Maria
AU - Corvò, Renzo
AU - Donato, Vittorio
N1 - Funding Information:
The institution of authors BAJF, MP, MZ, GM and MCL (IEO, European Institute of Oncology IRCCS, Milan) is partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 × 1000 funds. MZ was supported by a research grant from Accuray Inc. entitled “Data collection and analysis of Tomotherapy and CyberKnife breast clinical studies, breast physics studies and prostate study”. The sponsors did not play any role in the study design, collection, analysis and interpretation of data, nor in the writing of the manuscript, nor in the decision to submit the manuscript for publication. The authors wish to thank Lars Johannes Isaksson, MSc for the English revision of the manuscript. The authors wish to acknowledge all the Italian RT Directors who participated in the study. All the responders agreed for the publication of the results of the survey. Those who accepted to be acknowledged in the present work are listed in the Acknowledgments, Supplementary Materials .
Funding Information:
The institution of authors BAJF, MP, MZ, GM and MCL (IEO, European Institute of Oncology IRCCS, Milan) is partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 ? 1000 funds. MZ was supported by a research grant from Accuray Inc. entitled ?Data collection and analysis of Tomotherapy and CyberKnife breast clinical studies, breast physics studies and prostate study?. The sponsors did not play any role in the study design, collection, analysis and interpretation of data, nor in the writing of the manuscript, nor in the decision to submit the manuscript for publication. The authors wish to thank Lars Johannes Isaksson, MSc for the English revision of the manuscript. The authors wish to acknowledge all the Italian RT Directors who participated in the study. All the responders agreed for the publication of the results of the survey. Those who accepted to be acknowledged in the present work are listed in the Acknowledgments, Supplementary Materials. None. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. BAJF, MP, MZ, GM, RC and VD were responsible for conception and design of the study and wrote the first draft of the manuscript. AB, MB, GC, ARF, PF, MAG, DG, GI, AM, LM, IM, AM, MM, DM, RP, SP, VT, MT, MCL were responsible for data collection and wrote sections of the manuscript. BAJF, MP, MZ and GM were responsible for data analysis. All authors contributed to manuscript revision and read and approved the submitted version.
PY - 2021/2
Y1 - 2021/2
N2 - Not available
AB - Not available
UR - https://www.scopus.com/pages/publications/85096017803
U2 - 10.1016/j.radonc.2020.09.049
DO - 10.1016/j.radonc.2020.09.049
M3 - Editorial
SN - 0167-8140
VL - 155
SP - 120
EP - 122
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -